Stay updated on OPUS Clinical Trial: Natalizumab in Focal Epilepsy
Sign up to get notified when there's something new on the OPUS Clinical Trial: Natalizumab in Focal Epilepsy page.

Latest updates to the OPUS Clinical Trial: Natalizumab in Focal Epilepsy page
- Check4 days agoChange DetectedThe two screenshots show the Study Details page with no substantive changes to content or structure; only minor UI or rendering differences are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check11 days agoNo Change Detected
- Check33 days agoChange DetectedMajor update: version bumped to v3.2.0 and a government funding/operating-status notice added; previous version v3.1.0 removed.SummaryDifference3%

- Check40 days agoChange DetectedAppended version label (v3.1.0) and removal of multiple drug-safety related sections, indicating content consolidation and reorganization rather than new substantive content.SummaryDifference0.4%

- Check54 days agoChange DetectedUpdated page revision from v3.0.1 to v3.0.2; removed the Back to Top element. Overall, no substantive changes to core content or offerings.SummaryDifference0.2%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check69 days agoChange DetectedThe web page has been updated to include specific facility names and locations, as well as detailed information on drug safety and various pharmaceutical preparations, while removing some redundant location terms and outdated content.SummaryDifference3%

Stay in the know with updates to OPUS Clinical Trial: Natalizumab in Focal Epilepsy
Enter your email address, and we'll notify you when there's something new on the OPUS Clinical Trial: Natalizumab in Focal Epilepsy page.